The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved? [version 1; peer review: 3 approved]

Xu Luo\textsuperscript{1,2}, Katelyn L. O’Neill\textsuperscript{1}, Kai Huang\textsuperscript{1,2}

\textsuperscript{1}Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Alaska Medical Center, Omaha, NE, 68198-7696, USA
\textsuperscript{2}Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-6805, USA

Abstract

Bax and Bak, two functionally similar, pro-apoptotic proteins of the Bcl-2 family, are known as the gateway to apoptosis because of their requisite roles as effectors of mitochondrial outer membrane permeabilization (MOMP), a major step during mitochondria-dependent apoptosis. The mechanism of how cells turn Bax/Bak from inert molecules into fully active and lethal effectors had long been the focal point of a major debate centered around two competing, but not mutually exclusive, models: direct activation and indirect activation. After intensive research efforts for over two decades, it is now widely accepted that to initiate apoptosis, some of the BH3-only proteins, a subclass of the Bcl-2 family, directly engage Bax/Bak to trigger their conformational transformation and activation. However, a series of recent discoveries, using previously unavailable CRISPR-engineered cell systems, challenge the basic premise that undergirds the consensus and provide evidence for a novel and surprisingly simple model of Bax/Bak activation: the membrane (lipids)-mediated spontaneous model. This review will discuss the evidence, rationale, significance, and implications of this new model.

Keywords

Apoptosis, Bcl-2 family, Bax, Bak, BH3-only proteins, Bid, Bim, Bad, Bcl-xL, Mcl-1, Activator, Sensitizer, Direct activation, Indirect activation, Membrane-mediated Spontaneous activation, Mitochondrial outer membrane, auto-activation, de novo activation, retro-translocation, BH3 mimetics
Corresponding author: Xu Luo (xuluo@unmc.edu)

Author roles: Luo X: Conceptualization, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; O’Neill KL: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; Huang K: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by a pilot grant from the Nebraska Center for Cellular Signaling (P30GM106397) and National Institutes of Health (NIH) Grants R03CA205496 and R01GM118437 to Xu Luo.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Luo X et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Luo X, O’Neill KL and Huang K. The third model of Bax/Bak activation: a Bcl-2 family feud finally resolved? [version 1; peer review: 3 approved] F1000Research 2020, 9(Faculty Rev):935 https://doi.org/10.12688/f1000research.25607.1

First published: 06 Aug 2020, 9(Faculty Rev):935 https://doi.org/10.12688/f1000research.25607.1
Introduction

Apoptosis is a highly regulated form of cell death playing important roles in embryonic development, tissue homeostasis, and disease progression. In response to various death stimuli, cells often initiate a mitochondrial-dependent apoptotic pathway that involves mitochondrial outer membrane permeabilization (MOMP), formation of the apoptosome, and the activation of effector caspases. Generally considered the “point of no return”, MOMP irreversibly commits cells to apoptosis through the actions of Bax and Bak, two functionally similar effector proteins of the Bcl-2 family.

Since the identification of Bcl-2 in human follicular lymphoma and its discovery as the first anti-apoptotic oncogene over three decades ago, 17-18 proteins that share at least one of the four Bcl-2 homology domains (BH1-4) have been identified in the mammalian system as Bcl-2 family proteins, with the last member, Bmf, identified in 2001. The Bcl-2 family proteins are classified into anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1), pro-apoptotic effector (Bax, Bak, and Bok), and pro-apoptotic BH3-only proteins (Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa, and Puma) (Figure 1). Three types of interactions—1) BH3-only–anti-apoptotic, 2) anti-apoptotic–Bax/Bak, and 3) BH3-only–Bax/Bak—appear to govern the functional relationships among the Bcl-2 family members during apoptosis.

As the requisite effectors of MOMP, both Bax and Bak are kept in check under normal conditions. Bax is primarily in the cytosol as a globular-shaped monomeric protein consisting of nine α-helices, with helix 9 fitting into a hydrophobic groove. Bak has a similar structure but is localized to the mitochondrial outer membrane (MOM) through its helix 9. Both Bax and Bak are activated during apoptosis. The active forms of Bax/Bak are known to homo-oligomerize in the MOM, forming proteinaceous/lipidic pores that are responsible for the release of cytochrome c and other apoptogenic factors. The BH3-only and the anti-apoptotic Bcl-2 proteins regulate MOMP by promoting or suppressing the activation of Bax/Bak, respectively.

Bok has recently been shown to complement Bax/Bak in developmental cell death and to function as a non-canonical effector of MOMP in response to proteasome inhibition. However, since the loss of both Bax and Bak is sufficient to block apoptosis induced by most apoptotic stimuli, the role of Bok in apoptosis remains unclear.

As both Bax and Bak undergo a dramatic transformation from benign proteins to lethal effectors during apoptosis, the mechanism of their activation has been the subject of intense debate and is considered to be the “holy grail” of apoptosis research. Two competing but not mutually exclusive models, direct and indirect activation, had previously been proposed.

Direct activation

The first report of the direct interaction between a BH3-only protein and Bax/Bak was the identification of Bid as a BH3-containing death ligand that binds Bax. This finding led to the hypothesis that BH3-only proteins bind and activate Bax/Bak to initiate apoptosis. Subsequently, it was found that some BH3 domains, i.e. BidBH3 or BimBH3, have the ability to directly activate Bax/Bak and cause the release of cytochrome c from purified mitochondria. On the other hand, BH3 peptide from Bad (BadBH3) did not directly activate Bax/Bak but was able to bind to Bcl-2, displace BidBH3, and sensitize mitochondria to BidBH3-induced cytochrome c release. These findings formed the basis for the “direct activation” model, in which the BH3-only proteins are classified into two groups: the activators, which can directly activate Bax/Bak but can also be sequestered by the anti-apoptotic Bcl-2 proteins, and the sensitizers, which cannot directly activate Bax/Bak but are able to bind to the anti-apoptotic Bcl-2 proteins and sensitize cells to apoptosis. To induce apoptosis, the sensitizers bind the anti-apoptotic Bcl-2 proteins and displace the activators, which in turn directly bind to Bax/Bak, allosterically triggering their activation.

Although the initial classification listed Bid and Bim as direct activators because of the ability of the BH3 domain or the full-length protein to release dyes of large molecular weight from liposomes in the presence of inactive Bax and Bak, the list of direct activators has grown over the years to include Puma, Noxa, Bik, Bmf, and Hrk, although a range of potency has been reported. On the other hand, Bad has been a classic sensitizer, as the BadBH3 peptide has been used as a negative control for direct activators in liposome assays.

The interaction between a direct activator and Bax/Bak has been difficult to detect. This led to the hypothesis that activators only transiently engage Bax/Bak and activate them through a “hit and run” mechanism. The binding interface between an activator and Bax/Bak, while of great interest, has been controversial.

NMR analysis provided evidence that the BH3 peptide from Bim transiently binds to a “trigger site” between helix 1 and helix 6. However, other studies using Bax/Bak mutants that lack helix 9 found that a BidBH3 peptide binds the hydrophobic groove. The discrepancy was largely resolved by new studies suggesting that the initial binding is at the trigger site and that the ensuing conformational changes allow a more stable interaction between the BH3 peptide and the hydrophobic groove. However, the biological significance of binding at the trigger site has recently been challenged.

Over the years, the direct activation model has evolved into several variants. The embedded together model emphasizes the importance of the membrane as a platform for all of the interactions among the Bcl-2 family proteins during Bax/Bak activation, the unified model emphasizes that the anti-apoptotic Bcl-2 proteins not only sequester the activator BH3-only proteins but also suppress or sequester the activated Bax/Bak, and the interconnected model is highly analogous to the unified model but also contains a feed-forward mechanism of auto-activation. One unifying feature of these models is the direct attack and engagement of Bax/Bak by the activator BH3-only proteins as the initial triggering event leading to Bax/Bak activation.

Since the beginning of the last decade, direct activation has been widely accepted as the mechanism of Bax/Bak activation...
During apoptosis, however, as much of the supporting evidence has come from in vitro studies, the physiological significance of this model has not been fully addressed.

**Indirect activation**

Indirect activation, or the “displacement” model, was first proposed in two important studies. First, Bak was shown to be normally sequestered by Bcl-xL and Mcl-1 but displaced by BH3-only proteins. Second, in direct opposition to the direct activation model, Willis et al. demonstrated that apoptosis can be induced by “sensitizer” BH3-only proteins or mutants of “activators” that are unable to bind Bax/Bak, even in cells that are deficient for the three activator BH3-only proteins Bid, Bim, and Puma. These results gave rise to the indirect activation model, which proposed that the effectors Bax/Bak are constitutively active but are normally sequestered by the anti-apoptotic Bcl-2 proteins. During apoptosis, BH3-only proteins bind to anti-apoptotic Bcl-2 proteins and indirectly activate Bax/Bak by displacing and releasing sequestered active Bax/Bak (Figure 2B, top).

Although this model is consistent with the activation of Bak, it has difficulty explaining the activation of Bax. It was therefore hypothesized that a small fraction of Bax is constitutively active but is sequestered by the anti-apoptotic Bcl-2 proteins on the mitochondria. The BH3-only proteins release the active Bax, which in turn recruits cytosolic Bax to the mitochondria and activates it through an auto-activation mechanism (Figure 2B, bottom). However, this hypothesis does not address the
origin of the fraction of active Bax and the physiological relevance of auto-activation. Furthermore, as the indirect activation model was based on the key observation of Bax/Bak activation in Bid/Bim/Puma-deficient cells, the existence of additional activator BH3-only proteins made it more difficult to fully dissociate from the direct activation model. It is worth mentioning that in an elegant genetic knockin study in mice, Merino et al. compared the pro-apoptotic activities of wild-type Bim and its BH3-replacement mutants and presented data to suggest that neutralization of the anti-apoptotic Bcl-2 proteins is required but not sufficient for maximal apoptosis, suggesting the presence of both indirect and direct activation in vivo.

Functional redundancy and functional/physical connections: the Achilles’ heel of Bcl-2 research

A salient feature of the Bcl-2 family proteins is functional redundancy due to the presence of eight BH3-only, five anti-apoptotic, and two effector proteins. With multiple proteins sharing similar targets and functions in the same cell, it is difficult to pinpoint the real target, function, and mechanism of action of a particular protein.

As Bax and Bak are functionally redundant in many situations, our understanding of their functions was severely limited until a seminal study in which mouse embryonic fibroblasts (MEFs) doubly deficient for Bax and Bak were shown to be highly...
resistant to multiple apoptotic stimuli. This breakthrough ended years of frustration and established Bax and Bak as functionally equivalent and critical effectors of MOMP. However, the investigation into the functions and mechanisms of BH3-only proteins had been more challenging owing to the presence of eight BH3-only proteins, with seven of them potentially functioning as direct activators. In efforts to differentiate direct and indirect activation, loss-of-function studies have been carried out to eliminate the direct activators by generating Bid/Bim double knockout (DKO), Bid/Bim/Puma triple knockout (TKO), Bid/Bim/Puma/p53 quadruple knockout (QKO), and Bid/Bim/Puma/Noxa QKO cells. However, these cell models were insufficient to address this critical issue because of the presence of additional direct activators (i.e., Bik, Hrk, and Bmf) in those cells.

The second challenge is the complex functional and physical connections among the Bcl-2 family proteins. The anti-apoptotic Bcl-2 proteins interact with at least some of the BH3-only proteins constitutively. Therefore, in cells deficient for certain BH3-only proteins—notably, the Bid/Bim/Puma TKO and Bid/Bim/Puma/Noxa QKO cells—the loss of the BH3-only proteins should effectively increase the concentration of "unsequestered" or "active" Bcl-xL, Bcl-2, and Mcl-1, etc., whose total protein levels may not change. This increase would mean that these cells should have a greater capacity to sequester or suppress the active Bax/Bak and should at least in part explain the resistance of these TKOs and QKOs to apoptosis stimulation or the expression of the sensitizers.

"OctaKO" and "Bcl-2 allKO" cells: essential tools to reveal that direct activation is not required for BH3-only-mediated Bax/Bak activation and to establish the membrane (lipid)-mediated spontaneous model

In the past decade, the list of direct activator BH3-only proteins has grown to include Bid, Bim, Puma, Hrk, Noxa, Bik, and Bmf, which bind both Bax/Bak and the anti-apoptotic Bcl-2 proteins. Such a functional redundancy makes it near impossible to separate the functions of the direct activators and the sensitizers unless all of the direct activators are eliminated.

The advent of CRISPR technology made it possible to remove this roadblock. Through a sequential use of the CRISPR/Cas9 technology, HCT116 cells that lack all eight BH3-only proteins were generated and named OctaKO cells. This allowed for the interrogation of the function of individual BH3-only proteins without the participation of other BH3-only proteins. In this cell model, elimination of the two anti-apoptotic Bcl-2 proteins Bcl-xL and Mcl-1 by siRNA, pharmacological inhibition, or genetic elimination induced Bax/Bak activation and apoptosis efficiently. These results, for the first time, demonstrated that none of the direct activator BH3-only proteins is necessary for Bax/Bak activation once Bcl-xL/Mcl-1 are neutralized.

Similar strategies were used to generate the Bcl-2 allKO cells, which lost all eight pro-apoptotic BH3-only proteins, Bnip3 and Nix (non-apoptotic BH3-only proteins), the anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL, Mcl-1, A1, and Bcl-w), and Bax/Bak. These cells for the first time provided a clean slate to examine the functional relationship, through reconstitution, among Bcl-2 family proteins. Surprisingly, even minute amounts of Bax or Bak, re-introduced through a Dox-inducible expression system, were sufficient to kill these cells, and such killing was easily blocked by Bcl-xL. The highly efficient activation of Bax/Bak in Bcl-2 allKO cells is in stark contrast with the prediction from the direct activation model, which suggests that Bax should stay in the cytosol in the absence of an activator BH3-only protein. Importantly, mutants of Bax and Bak that lack their respective helix 9 (transmembrane [TM] domain) are incapable of homo-oligomerization and killing, and yet such activity was completely restored by the attachment of a heterologous TM domain, strongly suggesting that MOM association is sufficient for Bax/Bak activation.

These results formed the basis for a novel model of Bax/Bak activation, the membrane (lipid)-mediated spontaneous model (MMS), in which the BH3-only proteins activate Bax/Bak by inactivation or neutralization of the anti-apoptotic Bcl-2 proteins, instead of direct activation. This allows the Bax/Bak molecules to freely migrate to and diffuse in the MOM, homo-oligomerize, and form pores (Figure 2C, Figure 3). In this model, the driving force of Bax/Bak activation is essentially free diffusion and the well-documented MOM association through helix 9. Consistent with this model, cytosolic Bax was reported to be constitutively targeted to the mitochondria in non-apoptotic cells.

What are the targets of BH3-only proteins: anti-apoptotic Bcl-2 proteins, Bax/Bak, or both?

Our understanding of the functions of the BH3-only proteins was significantly enhanced when Chen et al. defined the binding specificity of various BH3-only proteins toward different anti-apoptotic Bcl-2 proteins. Using peptides of the BH3 domains of the BH3-only proteins, Chen et al. found that while Bid, Puma, and Bim are promiscuous in binding all five anti-apoptotic Bcl-2 proteins, Bad only selectively binds to Bcl-w, Bcl-xL, and Bcl-2, and Noxa binds only Mcl-1 and A1. The combination of Bad and Noxa potently induced apoptosis. Using derivatives of the OctaKO cells that also lack Bcl-xL or Mcl-1, the Huang et al. study confirmed and refined these findings by demonstrating that while Bad and Noxa preferentially bind Bcl-xL and Mcl-1, respectively, Bim, Bim, Puma, Bmf, Bik, and Hrk are promiscuous binders toward both.

The critical role of Bcl-xL and Mcl-1 in cell survival was first demonstrated in HeLa cells in which siRNA knockdown of both Bcl-xL and Mcl-1 resulted in robust apoptosis. This assay was subsequently carried out in multiple cell lines with deficiencies in several BH3-only proteins and ultimately the OctaKO cells. Without exception, the double siRNA knockdown induced robust apoptosis, strongly suggesting that Bcl-xL...
and Mcl-1 are the major targets of the BH3-only proteins during apoptosis. In support of Bcl-xL and Mcl-1’s critical role as gatekeepers against Bax/Bak activation, an elegant mouse genetic study found that while Mcl-1+/- Bcl-2+/– and Bcl-xL+/– Bcl-2+/- mice are almost normal, Mcl-1+/- Bcl-xL+/- mice displayed craniofacial defects.

Strikingly, Huang et al. found that Bad, the sensitizer protein, induced apoptosis as efficiently as the activator proteins tBid and Bim in the OctaKO derivative cells. Additionally, mutant activator BH3-only proteins with their BH3 domain replaced by that of Bad showed no difference from the wild-type activators in the induction of apoptosis in the OctaKO cells. Furthermore, tBid and Bim (both activators) as well as Bad (sensitizer) were found to induce apoptosis without distinguishing Bax from Bak, consistent with the conclusions of a recent in vitro study but in contrast to an earlier study. Lastly, tBid and Bim are unable to accelerate the spontaneous activation of Bax in the Bcl-2 allKO cells, suggesting that there is no functional/physical interaction between the activator BH3-only proteins and Bax/Bak after the neutralization of the anti-apoptotic Bcl-2 proteins. These results are incompatible with the direct activation model and argue strongly that there is no distinction between direct activators and sensitizers and that the only target of the BH3-only proteins is the anti-apoptotic Bcl-2 proteins. These findings unify the functions of BH3-only proteins and provide an elegantly simple model for apoptotic signaling (Figure 4B).

Of note, loss-of-function studies in mice have clearly demonstrated differential requirements for various BH3-only proteins in vivo. These observations are consistent with the notion that the BH3-only proteins’ roles are determined by their expression level, location, various regulations, and affinity with different anti-apoptotic Bcl-2 proteins, etc.

A bigger role for MOM in Bax and Bak activation

MOM has traditionally been viewed as a passive victim of activated Bax/Bak. However, some in vitro studies have suggested that MOM can serve as a platform for multiple interactions
among the Bcl-2 family proteins, including tBid–Bax, tBid–
Bcl-xL interactions, etc. \textsuperscript{31,85,86}. Results from the new series
of studies, especially the finding that the TD (helix 9) of
Bax/Bak was required and sufficient for Bax/Bak activation
in the absence of all BH3-only and anti-apoptotic Bcl-2
proteins, suggested a much bigger role for the MOM in the
regulation of Bax/Bak: the direct activator \textsuperscript{59,65,66}. In other words, the
MOM itself functions as the instigator of Bax/Bak’s attack
by directly recruiting and activating Bax/Bak. These results
also suggested a much bigger role for helix 9: the trigger site.
Importantly, the interaction between helix 9 and the MOM
is spontaneous, stable, and easily detectable in the cell. On
the other hand, the transient activator BH3-only–Bax/Bak
interaction observed \textit{in vitro} has been shown to be non-essential in
cellular assays.

How does the MOM activate Bax? First, as Bax has been shown
to exist in a dynamic equilibrium between the cytosol and
mitochondria, and that Bcl-xL constantly retro-translocates Bax/
Bak into the cytoplasm\textsuperscript{52,86,87}, it is essential that the anti-apoptotic
Bcl-2 proteins are inactivated by the BH3-only proteins or
other inhibitors before the MOM becomes a direct activator\textsuperscript{59,66}.
Second, a systematic mapping of the helices of Bax for their
capacity to associate with the MOM indicated that helices
4, 5, 6, and 9 contain mitochondrial targeting signals
\textsuperscript{88}. It is not difficult to imagine that the MOM has the
capacity to reconfigure the whole molecule through these
multiple lipid–protein interactions to promote Bax/Bak
homo-oligomerization upon the initial contact with helix 9.
Third, as helix 9 of Bax was recently shown to form dimers in
the MOM, such dimerization through helix 9 should provide
further impetus for homo-oligomerization and activation of
Bax/Bak molecules\textsuperscript{52,86-91}.

Thus, lipids are most likely the direct activator of Bax/Bak.
Consistent with this suggestion, cardiolipin was found to be

\textbf{Figure 4.} Apoptotic signaling through membrane (lipids)-mediated spontaneous activation of Bax/Bak. A) The intrinsic (mitochondrial-
dependent) apoptotic pathway based on the membrane (lipids)-mediated spontaneous (MMS) Bax/Bak activation model. B) The intrinsic
(mitochondrial-dependent) and extrinsic (death receptor-mediated) apoptotic pathways based on the MMS activation model. Apaf-1, apoptotic
protease activating factor-1; Casp, caspase; Cyt c, cytochrome c; FADD, Fas associated death domain protein; MOM, mitochondrial outer
membrane; SMAC, second mitochondria-derived activator of caspase; XIAP, X-linked inhibitor of apoptosis protein.

\begin{itemize}
  \item How does the MOM activate Bax? First, as Bax has been shown
to exist in a dynamic equilibrium between the cytosol and
  \item mitochondria, and that Bcl-xL constantly retro-translocates Bax/
  Bak into the cytoplasm\textsuperscript{52,86,87}, it is essential that the anti-apoptotic
  Bcl-2 proteins are inactivated by the BH3-only proteins or
  other inhibitors before the MOM becomes a direct activator\textsuperscript{59,66}.
  \item Second, a systematic mapping of the helices of Bax for their
capacity to associate with the MOM indicated that helices
4, 5, 6, and 9 contain mitochondrial targeting signals
\textsuperscript{88}. It is not difficult to imagine that the MOM has the
capacity to reconfigure the whole molecule through these
multiple lipid–protein interactions to promote Bax/Bak
homo-oligomerization upon the initial contact with helix 9.
  \item Third, as helix 9 of Bax was recently shown to form dimers in
the MOM, such dimerization through helix 9 should provide
further impetus for homo-oligomerization and activation of
Bax/Bak molecules\textsuperscript{52,86-91}.
\end{itemize}
required for Bax activation. Interestingly, it has been shown that non-ionic detergents, which somewhat mimic the lipid bilayer environment, are excellent activators of Bax/Bak.

It is therefore of great interest to test if certain lipid compositions can support Bax activation without the activator BH3-only proteins, even though the commonly used preparations prohibit such activity. A liposome composition that supports the constitutive activation of Bax in the absence of tBid should recapitulate what is observed in the cell.

MOM proteins may help recruit Bax to the MOM. VDAC2, despite earlier observations that it sequesters and suppresses Bak, has recently been shown to be required for the mitochondrial translocation of Bax. In addition, the mitochondrial fission regulator Drp1 has been shown to play a positive role in the regulation of Bax/Bak activation. As both VDAC2 and Drp1 are present in the Bcl-2 aIKO cells, it is possible that these proteins play a positive role in recruiting Bax/Bak along with the lipids to allow spontaneous localization.

**De novo activation versus auto-activation of Bax/Bak**

Based on results from a liposome study with an extended BH3 peptide and Bax, it has been hypothesized that active Bax uses its BH3 domain to directly bind and activate an inactive Bax to accelerate Bax activation. This putative feed-forward mechanism is termed “auto-activation”. In support of this hypothesis, during apoptosis, Bax/Bak undergo conformational changes and expose the BH3 domain. Auto-activation has recently been suggested to be a critical feed-forward mechanism for Bax/Bak activation in response to DNA damage and other death stimuli. However, the origin of the first active Bax/Bak molecule and the physiological significance of auto-activation are unclear. Furthermore, there are no experimental data to support the hypothesis that active Bax can recruit cytosolic Bax to the mitochondria.

Both the direct activation and MMS model probe the mechanism of Bax/Bak’s de novo activation. Although there is potential involvement of auto-activation as a feed-forward mechanism to sustain Bax/Bak activation through homo-oligomerization, it is not the triggering mechanism that initiates the activation of Bax/Bak per se. For example, although the “interconnected” model contains an element of auto-activation, the origin of the first active Bax/Bak molecules was attributed to direct activation.

**How do the BH3 mimetics work?**

Thanks to a close collaboration between basic researchers and the pharmaceutical industry, numerous small molecules that mimic the structures of the BH3 domains of the BH3-only proteins have been developed to kill cancer cells and overcome resistance. For example, through NMR-based fragment screen and structure-guided design, ABT-737 was developed to mimic BadBH3, and it is highly selective against Bcl-xL, Bcl-2, and Bcl-w. Using similar strategies, Kotschy et al. designed S63845, a highly selective inhibitor of Mcl-1. Remarkably, venetoclax, a BH3 mimic and the first small-molecule drug that disrupts a protein–protein interaction, was FDA approved for the treatment of a subtype of chronic lymphocytic lymphoma. However, the obvious question is this: which interaction does it disrupt in the cell? According to the direct activation model, the Bcl-2 mimetic disrupts two interactions: activator BH3-only–Bcl-2 and Bax/Bak–Bcl-2. The liberated activator BH3-only proteins then directly activate the liberated Bax or Bak. However, this scenario is difficult to prove experimentally and is not consistent with the observation that combinations of BH3 mimetics against Bcl-xL and Mcl-1 are sufficient to kill OctaKO HCT116 cells. Such an observation is explained by the MMS model, in which the BH3 mimetics neutralize Bcl-xL/Mcl-1 and allow the MOM to directly activate Bax/Bak. It is of interest, however, that over-expression of Bcl-xL confers resistance to the apoptotic effects of Bcl-xL-targeting BH3 mimetics, suggesting limitations of these small-molecule inhibitors.

**How do the anti-apoptotic Bcl-2 suppress Bax/Bak activation?**

It is well established that Bax exists mostly as an inactive and monomeric protein in cytosol. However, the spontaneous activation of Bax in the Bcl-2 aIKO strongly suggests that Bax is constantly trying to land on the mitochondria through its C-terminal tail, consistent with the observation of a natural tendency of Bax to move to the mitochondria. It is also clear that Bcl-xL and Mcl-1 play a critical role in keeping Bax in the cytosol. How do Bcl-xL and Mcl-1 achieve this feat? Edlich et al. demonstrated that Bcl-xL has the ability to push the mitochondrially localized Bax molecules into the cytosol. Interestingly, Todt et al. demonstrated that Bak can also be retro-translocated by Bcl-xL, albeit at a much slower rate. However, the molecular mechanisms of such a retro-translocation activity remain unclear. Nevertheless, helix 9 of Bcl-xL may play a role in mediating this mysterious activity, through which the Bax molecule may be re-packed into a globular shape so that helix 9 can fit into the hydrophobic groove. Once this re-packaging is finished, Bax is expected to leave the mitochondria and become cytosolic. The molecular details of such extraordinary activity will be a focus of future studies.

**The membrane (lipids)-mediated spontaneous model versus indirect and direct activation models**

The MMS model combines some important elements from both the direct and the indirect activation models yet for the first time introduced a new interaction as the trigger for Bax/Bak activation (Figure 2 and Figure 3, Table 1). First, in agreement with indirect activation, the MMS model proposes that there is no hierarchy among the BH3-only proteins and the only target of the BH3-only proteins are the anti-apoptotic Bcl-2 proteins. Second, similar to the direct activation model, the MMS model proposes that a de novo direct activation, instead of de-repression, is the mechanism of Bax/Bak activation. However, the MOM, instead of the activator BH3-only proteins, is the direct activator. Third, the MMS model proposes that...
helix 9 is the trigger site for Bax/Bak activation. Instead of a transient, “hit-and-run” interaction as proposed in the direct activation model, the interaction between Bax/Bak and the MOM is visible and stable and consists of multiple interfaces once homo-oligomerization initiates.

Some questions remain to be answered: what are the molecular details of MOM-mediated spontaneous Bax/Bak activation? What are the dynamics of the helix 9–hydrophobic groove interaction in the cytosol? Can in vitro liposome assays recapitulate the MMS model? What are the mechanisms of retro-translocation?

**Conclusion**

The balance among the Bcl-2 family members, namely the relative amounts of the BH3-only proteins and the anti-apoptotic Bcl-2 proteins, determines the fate of the cell through the activation of Bax and Bak. According to the MMS model, during apoptotic signaling, once all the Bcl-xL/Mcl-1 molecules are neutralized by the BH3-only proteins, Bax/Bak spontaneously (through free diffusion) associate with the MOM, which acts as a direct activator to trigger Bax/Bak’s self-aggregation and pore formation. This remarkably efficient and simple mechanism might provide new thinking on pharmacological intervention. For example, is it possible to manipulate the lipid composition or other properties of the MOM to either accelerate or slow down the attack by the Bax/Bak molecules? Also, since helix 9’s exposure and access to the MOM is essential to this process, is it possible to design small molecules to promote or suppress the dislodging of helix 9 from the hydrophobic groove of Bax/Bak, therefore modulating the targeting of these molecules to the mitochondria?

**Acknowledgements**

We are grateful to Dr. Keith Johnson (Department of Oral Biology and Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, USA) for his suggestions and critical reading of the manuscript. Xu Luo dedicates this work to the loving memory of his father, Dr. Shiqi Luo, one of the finest neurosurgeons ever, whose encouragement, support, and advice made the work possible.

**References**

1. Danial NN, Korsmeyer SJ: Cell death: Critical control points. Cell. 2004; 116(2): 205–19. Published Abstract | Publisher Full Text

2. Jiang X, Wang X: Cytochrome C-mediated apoptosis. Annu Rev Biochem. 2004; 73: 87–106. Published Abstract | Publisher Full Text

3. Kalkavan H, Green DR: MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018; 25(1): 46–55. Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

4. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986; 47(1): 19–28. PubMed Abstract | Publisher Full Text

5. Tsujimoto Y, Cossman J, Jeffe E, et al: Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985; 228(4706): 1440–3. Published Abstract | Publisher Full Text

6. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988; 335(6189): 440–2. Published Abstract | Publisher Full Text

7. Cory S, Huang DCS, Adams JM: The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 2003; 22(53): 5850–607. PubMed Abstract | Publisher Full Text

---

**Table 1. Comparison of the three models of BH3-only-mediated Bax/Bak activation.**

| Model of Bax/Bak Activation | Targets of the BH3-only proteins | BH3-only–Bax/Bak Interaction | Activation Mechanism | Direct Activator | Trigger Site on Bax/Bak | Driving Force |
|-----------------------------|----------------------------------|-----------------------------|---------------------|-----------------|-------------------------|--------------|
| Indirect Activation (Displacement) | Anti-apoptotic Bcl-2 proteins | None | Displacement and De-repression | None | None | Stable BH3-only–Bcl-xL/Mcl-1 interaction |
| Direct Activation | Bax/Bak and anti-apoptotic Bcl-2 proteins | Yes | De novo and direct activation | Activator BH3-only proteins | Helices 1/6 or the hydrophobic groove | Transient BH3 (BH3-only)–groove (Bax/Bak) interaction |
| Membrane (lipids)-mediated Spontaneous Activation | Anti-apoptotic Bcl-2 proteins | None | De novo and direct activation | Mitochondrial outer membrane (lipids) | C-terminal tail (helix 9) | Stable BH3-only–Bcl-xL/Mcl-1 interaction, free diffusion, and stable Bax/Bak α9–membrane interaction |
BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011; 44(4): 517–31. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

31. Lovei JF, Billen LP, Bindner S, et al.: Membrane Binding by tBid Initiates an Ordered Series of Events Culinating in Membrane Permeabilization by Bax. Cell. 2008; 135(6): 1074–84. 
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

32. Bogner C, Kale J, Pogmore J, et al.: Allosteric Regulation of B3H Proteins in Bax-L Complexes Enables Switch-like Activation of Bax. Mol Cell 2020; 77(4): 901–912.e9. 
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

33. Dai H, Smith A, Meng XW, et al.: Transient binding of an activator BH3 domain to the Bag BH3-bonding groove initiates Bag oligomerization. J Cell Biol. 2011; 191(4): 39–48. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

34. Du H, Wolf J, Schaar B, et al.: BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem. 2011; 286(1): 491–501. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

35. Hoffings C, Anwar K, Ninnis RL, et al.: Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax and show no preference for Bax versus Bax. Cell Death Dis. 2015; 6(4): e1735. 
PubMed Abstract | Publisher Full Text | Free Full Text

36. Chen HC, Kanal M, Insue-Yamashita A, et al.: An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol. 2015; 17(10): 1270–81. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

37. Edwards AL, Gavathiotis E, LaBelle JL, et al.: Multimodal Interaction with BCL-2 Family Proteins Underlies the Proapoptotic Activity of PUMA B3H. Chem Biol. 2013; 20(7): 888–902. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

38. Cartron PF, Gallenne T, Bouras G, et al.: The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell. 2004; 14(5): 507–18. 
PubMed Abstract | Publisher Full Text | Free Full Text

39. Gavathiotis E, Reyna DE, Davis ML, et al.: BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell. 2010; 40(3): 481–92. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

40. Gavathiotis E, Suzuki M, Davis ML, et al.: BAX activation is initiated at a novel interaction site. Nat Struct Mol Biol. 2013; 20(5): 589–97. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

41. Gavathiotis E, Grace CR, Lambi F, et al.: Bid-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol. 2013; 20(5): 589–97. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

42. Czabotar PE, Westphal D, Dawson G, et al.: Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell. 2013; 152(3): 519–31. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

43. Moldoveanu T, Grace CR, Lambi F, et al.: Bid-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol. 2013; 20(5): 589–97. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

44. Brouwer JM, Lan P, Cowan AD, et al.: Conversion of Bim-BH3 from Activator to Inhibitor of Bak through Structure-Based Design. Mol Cell. 2017; 68(4): 659–672.e9. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

45. Robin AY, Krishna Kumar K, Westphal D, et al.: Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis. 2015; 6(7): e1809–e1809. 
PubMed Abstract | Publisher Full Text | Free Full Text

46. Brouwer JM, Westphal D, Dawson G, et al.: Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol Cell. 2013; 48(6): 938–48. 
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

47. Leschiner ES, Braun CR, Bird GH, et al.: Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci U S A. 2013; 110(11): E986–99. 
PubMed Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation

48. Dengler MA, Robin AY, Gibson L, et al.: BAX Activation: Mutations Near Its Proposed Non-canonical BH3 Binding Site Reveal Allosteric Changes Controlling Mitochondrial Association. Cell Rep. 2019; 27(2): 359–373.e6. 
PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

49. Peng R, Tong JS, Li H, et al.: Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation. Cell Death
Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell 2005; 17(3): 393–403. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

70. Lopez H, Zhang L, George NM, et al.: Perturbation of the Bcl-2 network and an induced noxa/Bcl-xL interaction under mitochondrial dysfunction after DNA damage. J Biol Chem. 2010; 285(26): 20156–62. PubMed Abstract | Publisher Full Text | Full Text

71. Zhang L, Lopez H, George NM, et al.: Selective involvement of BH3-only proteins and differential targeting of Noxa in diverse apoptotic pathways. Cell Death Differ. 2011; 18(5): 764–73. PubMed Abstract | Publisher Full Text | Full Text

72. Grabow S, Kueh AJ, Ke F, et al.: Subtle Changes in the Levels of Bcl-2 Proteins Cause Severe Cranialofacial Abnormalities. Cell Rep. 2018; 24(12): 3285–3295.e4. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

73. Sarosiek KA, Chi X, Bachman JA, et al.: BID Preferentially Activates BAK while BIM Preferentially Activates BAX. Affecting Chemotherapy Response. Mol Cell. 2013; 51(6): 751–65. PubMed Abstract | Publisher Full Text | Full Text

74. Coultas L, Boullet P, Loveless KL, et al.: Concomitant loss of proapoptotic BH3-only Bcl-2 antagonists Bik and Bim arrests spermatogenesis. EMBO J. 2005; 24(22): 3963–73. PubMed Abstract | Publisher Full Text | Full Text

75. Coultas L, Boullet P, Stanley EG, et al.: Proapoptotic Bcl-3 Bcl-2 Family Member Bik/Bik/Nbk is Expressed in Hemopoietic and Endothelial Cells but is Redundant for Their Programmed Death. Mol Cell Biol. 2004; 24(5): 1570–81. PubMed Abstract | Publisher Full Text | Full Text

76. Boullet P, Metcalf D, Huang DC, et al.: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999; 286(5440): 1735–40. PubMed Abstract | Publisher Full Text | Full Text

77. Yin XM, Wang K, Gross A, et al.: Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999; 400(6747): 886–91. PubMed Abstract | Publisher Full Text | Full Text

78. Shibue T, Takeda K, Oda E, et al.: Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2005; 19(18): 2239–8. PubMed Abstract | Publisher Full Text | Full Text

79. Jeffers JR, Parganas E, Lee Y, et al.: Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003; 4(4): 321–8. PubMed Abstract | Publisher Full Text | Faculty Opinions Recommendation

80. Villunger A, Michałak EM, Coultas L, et al.: p53- and drug-induced apoptotic responses mediated by Bcl-3-only proteins puma and noxa. Science. 2003; 302(5647): 1036–8. PubMed Abstract | Publisher Full Text | Full Text

81. Hübner A, Cavanagh-Kyros J, Rincon M, et al.: Functional Cooperation of the Proapoptotic Bcl2 Family Proteins Bmf and Bim in Vivo. Mol Cell Biol. 2010; 30(1): 99–105. PubMed Abstract | Publisher Full Text | Full Text

82. Hausmann M, Leucht K, Pioner C, et al.: BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. J Biol Chem. 2011; 286(30): 26533–40. PubMed Abstract | Publisher Full Text | Full Text

83. Coultas L, Terzano S, Thomas T, et al.: Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis. J Cell Sci. 2007; 120(Pt 12): 2044–52. PubMed Abstract | Publisher Full Text | Full Text

84. Ranger AM, Zha J, Harada H, et al.: Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003; 100(16): 9324–9. PubMed Abstract | Publisher Full Text | Full Text

85. Huang K, Zhang L, O'Neill KL, et al.: Cleavage by Caspase 8 and Mitochondrial Membrane Association Activate the BH3-only Protein Bid during TRAIL-induced Apoptosis. J Biol Chem. 2018; 293(22): 11843–51. PubMed Abstract | Publisher Full Text | Full Text

86. García-Sáez AJ, Ries J, Orzáez M, et al.: Membrane promotes BID interaction with BCL(XL). Nat Struct Mol Biol. 2009; 16(11): 1178–85. PubMed Abstract | Publisher Full Text | Full Text

87. Todé F, Cakir Z, Reichenbach F, et al.: Differential retrotranslocation of mitochondrial Bax and Bak. EMBO J. 2014; 33(1): 67–80. PubMed Abstract | Publisher Full Text | Full Text | Faculty Opinions Recommendation

88. George NM, Targy N, Evans JJ, et al.: Bax contains two functional mitochondrial targeting sequences and translocates to mitochondria in a conformational change- and homo-oligomerization-driven process. J Biol Chem. 2010; 285(3): 1384–92. PubMed Abstract | Publisher Full Text | Full Text

89. Gahl RF, He Y, Yu S, et al.: Conformational Rearrangements in the Pro-Apoptotic Protein, Bax, as It Inserts Into Mitochondria. J Biol Chem. 2014; 289(47): 32871–82. PubMed Abstract | Publisher Full Text | Full Text | Faculty Opinions Recommendation

Page 12 of 14
et al., Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem. 1997; 272(21): 13829–34.

94. Cheng EHY, Sheiko TV, Fisher JK, et al.: VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science. 2003; 301(5632): 513–7.

95. Ren D, Kim H, Tu HC, et al.: The VDAC2-BAK rheostat controls thymocyte survival. Sci Signal. 2009; 2(85): n48.

96. Chiu HS, Li MX, Tan KL, et al.: VDAC2 enables BAX to mediate apoptosis and limit tumor development. Nat Commun. 2018; 9(1): 4976.

97. Lauterwasser J, Todt F, Zerbes RM, et al.: The porin VDAC2 is the mitochondrial platform for Bax retrotranslocation. Sci Rep. 2016; 6: 32994.

98. Karbowski M, Lee YJ, Gaume B, et al.: Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol. 2002; 158(6): 931–8.

99. Milani M, Beckett AJ, Al-Zebeeby A, et al.: DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis. Cell Death Dis. 2019; 10: 117.

100. Montessuit S, Somasekharan SP, Terrones O, et al.: Membrane Remodeling Induced by the Dynamin-Related Protein Drp1 Stimulates Bax Oligomerization. Cell. 2010; 142(6): 889–901.

101. Tan C, Dlugosz PJ, Peng J, et al.: Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2. J Biol Chem. 2006; 281(21): 14764–75.

102. Dai H, Ding H, Meng XW, et al.: Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev. 2015; 29(20): 2140–52.

103. Ashkenazi A, Fairbrother WJ, Levenson JD, et al.: From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017; 16(4): 273–84.

104. Ottersdorf T, Elmore SW, Shoemaker AR, et al.: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042): 677–81.

105. Kotschy A, Szaivic Z, Murray J, et al.: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016; 538(6626): 477–82.

106. Green DR: A B3 Mimetic for Killing Cancer Cells. Cell. 2016; 165(7): 1560.

107. Corry S, Roberts AW, Colman PM, et al.: Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends Cancer. 2016; 2(8): 443–60.

108. Merino D, Kelly GL, Lessene G, et al.: BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell. 2018; 34(6): 879–91.

109. Souers AJ, Levenson JD, Boghaert ER, et al.: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19(2): 202–8.

110. Greaves G, Milani M, Butterworth M, et al.: BH3-only proteins are dispensable for apoptosis induced by pharmaceutical inhibition of both MCL-1 and BCL-X L. Cell Death Dis. 2019; 10(6): 1037–47.

111. Pécot J, Mallet L, Le Pen J, et al.: Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Rep. 2016; 17(12): 3347–58.

112. Inoue-Yamauchi A, Jeng PS, Kim K, et al.: Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017; 8: 16078.

113. Todd F, Cakir Z, Reichenbach F, et al.: The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria. Cell Death Dis. 2013; 4(6): 333–42.

114. Reyna DE, Gardner TP, Lopez A, et al.: Direct Activation of BAX by BTKA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell. 2017; 32(4): 490–505.e10.

115. Gardner TP, Aragalan D, Reyna DE, et al.: Small-molecule allosteric inhibitors of BAX. Nat Chem Biol. 2019; 15(4): 322–30.
Open Peer Review

Current Peer Review Status: ✔️ ✔️ ✔️

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

1. **Vishva Dixit**
   Department of Physiological Chemistry, Genentech, South San Francisco, CA, USA
   **Competing Interests:** No competing interests were disclosed.

2. **Andrew Gilmore**
   Wellcome Trust Centre for Cell/Matrix Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
   **Competing Interests:** No competing interests were disclosed.

3. **Andreas Strasser**
   The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC, Australia
   **Competing Interests:** Andreas Strasser is an employee of The Walter and Eliza Hall Institute. This Institute receives milestone payments and royalties from the sale of venetoclax. Andreas Strasser also has a collaboration with Servier for the development of MCXL01 inhibitors for cancer therapy.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com